Trabectedin CAS 114899-77-3 Purity ≥98.0% (HPLC) Synthetic Route
Shanghai Ruifu Chemical Co., Ltd. is the leading supplier of Trabectedin (CAS: 114899-77-3) with high quality, please contact us by e-mail:alvin@ruifuchem.com
Trabectedin is a tetrahydroisoquinoline alkaloid with effective anti-tumor activity and is isolated from ecteinascidia turbinata, but due to the low content, the separation and purification process was extremely complex, with only less than one gram of Trabectedin being extracted from each ton of ecteinascidia turbinata. Due to its extremely complex molecular structure, Trabectedin is known as "the Mount Everest of drug synthesis". Spent three years exploring an alternative approach and adopted a total synthesis route, starting from the readily available natural substance tyrosine, and after only 26 reactions, obtained this drug molecule with a total yield of 1.6%. The researchers conducted detailed process studies on each step of the synthesis route for Trabectedin, summarized technical parameters, and ultimately achieved commercial production.
| Chemical Name | Trabectedin |
| Synonyms | Ecteinascidin 743; ET-743; NSC 648766; Yondelis |
| Stock Status | In Stock |
| CAS Number | 114899-77-3 |
| Molecular Formula | C39H43N3O11S |
| Molecular Weight | 761.84 |
| Melting Point | >143℃(lit.) |
| COA | Available |
| Origin of Product | Shanghai, China |
| Product Categories |
API (Active Pharmaceutical Ingredient) |
| Brand | Ruifu Chemical |
Package: Bottle, Aluminium foil bag, or as customer's requirement.
Storage Condition:Keep the container tightly closed. Store in a cool, dry, well-ventilated warehouse.
Shipping:Deliver to worldwide by FedEx Express. Provide fast and reliable delivery.
Trabectedin (CAS: 114899-77-3), On October 23, 2015, FDA approved the listing of Trabetidinol (Trabectedin), a drug of Janssen (Janssen) Company, a subsidiary of Johnson & Johnson, under the trade name Yondelis. For the treatment of patients with non-resectable or metastatic liposarcoma and leiomyosarcoma who have received chemotherapy containing an anthracycline. Tribetete was designated as an alkylating agent as a cytotoxic drug. In 2007, EMEA approved it to be listed for the first time in Europe for the treatment of advanced soft tissue sarcoma. Later, it was approved to treat recurrent ovarian cancer in Europe and Canada. The manufacturers are Spanish biotechnology company Zeltia and Johnson and Johnson.
